SANDOZ OLOPATADINE 0.1 %
OLOPATADINE (OLOPATADINE HYDROCHLORIDE) : 0.1 % · DIN 02358913 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ OLOPATADINE?
SANDOZ OLOPATADINE 0.1 % contains OLOPATADINE (OLOPATADINE HYDROCHLORIDE) : 0.1 %. It is listed in the Health Canada Drug Product Database under DIN 02358913, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 04-Feb-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ OLOPATADINE used for?
Treatment of allergic conjunctivitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02358913 |
|---|---|
| Brand name | SANDOZ OLOPATADINE |
| Generic / active ingredient | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) : 0.1 % |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 0.1 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01GX09 OLOPATADINE |
| AHFS class | 52:02.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Feb-2013 |
| Original market date | 2013-02-04 00:00:00 |
How is it administered?
One to two drops in each affected eye twice daily. If a dose is missed, take as soon as possible; do not double dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 4° - 30°C. Discard the container at the end of treatment.
How is it supplied?
Plastic DROP-TAINER® dispensers containing 5 mL.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation or component of the container.
Warnings and precautions
For topical ocular use only. Not for injection or oral use. Contains benzalkonium chloride; remove contact lenses prior to use and wait 15 minutes. May cause temporary blurred vision.
Is OLOPATADINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 31 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01GX09 OLOPATADINE. 9 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MINT-OLOPATADINE | 0.1 % | SOLUTION | MINT PHARMACEUTICALS INC | MARKETED | DIN 02422727 |
| MINT-OLOPATADINE 0.2% | 0.2 % | SOLUTION | MINT PHARMACEUTICALS INC | MARKETED | DIN 02508605 |
| OLOPATADINE | 0.1 % | SOLUTION | SANIS HEALTH INC | MARKETED | DIN 02521172 |
| OLOPATADINE 0.2% | 0.2 % | SOLUTION | SANIS HEALTH INC | MARKETED | DIN 02541653 |
| PATADAY | 0.2 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02362171 |
| PATANOL | 0.1 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02233143 |
| PAZEO | 0.7 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02458551 |
| SANDOZ OLOPATADINE 0.2% | 0.2 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02420171 |
| ACT OLOPATADINE 0.1% | 0.1 % | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02403986 |
| ACT OLOPATADINE 0.2% | 0.2 % | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02404095 |
Who else supplies OLOPATADINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OLOPATADINE appears in 43 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.